CODX — Co-Diagnostics Income Statement
0.000.00%
Last trade - 00:00
- $36.89m
- -$21.66m
- $6.81m
- 36
- 36
- 84
- 51
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.215 | 74.6 | 97.9 | 34.2 | 6.81 |
Cost of Revenue | |||||
Gross Profit | 0.103 | 58 | 86.3 | 28.7 | 2.63 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 6.11 | 32.9 | 51.8 | 53.3 | 48.4 |
Operating Profit | -5.89 | 41.7 | 46.1 | -19.1 | -41.6 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -6.2 | 42.6 | 45.6 | -18.8 | -38.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -6.2 | 42.5 | 36.7 | -14.2 | -35.3 |
Net Income Before Extraordinary Items | |||||
Net Income | -6.2 | 42.5 | 36.7 | -14.2 | -35.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -6.2 | 42.5 | 36.7 | -14.2 | -35.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.37 | 1.52 | 1.23 | -0.295 | -1.23 |